The impact of empagliflozin on kidney injury molecule-1: A subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial

Nephrology Dialysis Transplantation

Volumn 35, Issue 5, 2020, Pages 895-897

  Opingari, Erika ^a,b   Verma, Subodh ^a,b,c   Connelly, Kim A ^a,b   Mazer, Cyril David ^a,b,c   Teoh, Hwee ^a   Quan, Adrian ^a   Zuo, Fei ^a   Pan, Yi ^a   Bhatt, Deepak L ^d   Zinman, Bernard ^b,e   Leiter, Lawrence A ^a,b,c   Yan, Andrew T ^a,b   Cherney, David Z I ^b,f   Gilbert, Richard E ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; HEMOGLOBIN A1C; KIDNEY INJURY MOLECULE 1; PLACEBO;

ADULT; CARDIOVASCULAR DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSURIA; HUMAN; KIDNEY INJURY; KIDNEY TUBULE; LETTER; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; URINARY EXCRETION;

EID: 85084326881     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfz294     Document Type: Letter

References (8)

1. Wanner C, Inzucchi SE, Lachin JM et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016; 375: 323-334
2. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-657
3. Mosenzon O, Wiviott SD, Cahn A et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019; 7: 606-617
4. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. NEngl JMed 2019; 380: 2295-2306
5. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393: 31-39
6. Gilbert RE. Proximal tubulopathy: prime mover and key therapeutic target in diabetic kidney disease. Diabetes 2017; 66: 791-800
7. Verma S, Mazer CD, Yan AT et al. Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes and coronary artery disease: the EMPAHEART CardioLink-6 Randomized Clinical Trial. Circulation 2019; 140: 1693-1702
8. Dekkers CCJ, Petrykiv S, Laverman GD et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab 2018; 20: 1988-1993